Dataset Viewer
text
stringlengths 1
2.37k
|
|---|
Wang W, Ma L, Zhang Y, et al.
|
The results of some of these trials have expanded the indications for ARB.
|
4 | DISCUSSION The treatment of chronic diseases such as hypertension and dyslipidemia can be negatively impacted by poor levels of patient compliance with medication.
|
2019;41(1):e84–94.
|
4 78.
|
71–1.
|
3–4.
|
18.
|
2021;39(1):23–37.
|
Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG.
|
49 (1.
|
2017 Apr 25;4:CD008893.
|
8 NS -2.
|
2004;11:110–121.
|
Armolipid Plus®) on BP and high BP complications [25].
|
Although the mechanism (s) involved and the extent of BP reduction with statin use remain to be clearly elucidated, it is believed that statins lower BP by increasing nitric oxide bioavailability and improving arterial compliance.
|
Abstract Single risk factors, such as hypertension and dyslipidemia, can combine to exacerbate the development and severity of cardiovascular disease.
|
84 (0.
|
BP levels at each visit for patients in either Group A or Group T.
|
5).
|
There is a mentioned lipid improving effect ascribed to amlodipine alone apart from atorvastatin in both studies.
|
Son M, Guk J, Kim Y, et al.
|
1136/heartjnl-2011-300867.
|
2% were not at goal for A1C, 64.
|
Whole study cohort Overall, a statistically significant (p<0.
|
52 1.
|
Low-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk management.
|
1080/ 10408 39080 21453 44.
|
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
|
An 8-year follow-up in the Copenhagen Male Study.
|
2012;1821:502–512.
|
[33] Hence, lipitension contributes to atherosclerosis and the resultant vascular risk, through its effects on the level of the endothelium.
|
Results: Overall, ARB treatment reduced BP levels significantly (p<0.
|
001 Multiadjusted* HR (95% CI) 1.
|
Hypertension.
|
2012;3:39–40.
|
2020;78(7–8):659–66.
|
226 C.
|
Even as the cholesterol-lowering drugs may favorably affect blood pressure, some blood pressure–lowering drugs, such as RAAS blockers and CCBs have a neutral or some beneficial effect on serum lipid levels.
|
The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009).
|
2009;30:554–558 (Chinese with English Abstract).
|
The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy.
|
88) −51.
|
Indian Journal of Endocrinology and Metabolism / Mar-Apr 2012 / Vol 16 | Issue 2 240 LIPITENSION: Interplay between dyslipidemia and hypertension Jamshed J.
|
Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y.
|
83) Chronic kidney disease, n (%) 3 (4.
|
7 20.
|
28 mmol/L, 95% CI – 0.
|
75 to 1.
|
Even though the persistence of prespecified lipid changes during extended therapy is unresolved due to fragmentary observations, considerable data suggest that it continues on the long term [58].
|
In the last years, the Italian Society of Hypertension (SIIA) and ESH published statements summarizing the best available evidence of efficacy for nutraceuticals with proved BP-lowering effect [15, 16].
|
The coexistence of these risk factors may overshadow the mortality reduction, which is acheived by keeping hypertension under control.
|
1001/ jama.
|
[16] Kirk JK.
|
Ried K, Sullivan TR, Fakler P, Frank OR, Stocks NP.
|
Sharifi N, Tabrizi R, Moosazadeh M, Mirhosseini N, Lankarani KB, Akbari M, Chamani M, Kolahdooz F, Asemi Z.
|
4 28.
|
25) 2.
|
284* BMI (kg/m2) 30.
|
28.
|
41 3.
|
Influence of aging and other cardiovascular risk factors on baroreflex sensitivity.
|
Nutr Rev.
|
7±13.
|
These findings suggest the need for the intensive control of lipitension as a component of global risk factors in patients with CAD.
|
3±4.
|
61.
|
Follow-up Examinations The outcome measure of this study was the time until the development of hypertension.
|
81–1.
|
9±5.
|
The difference between the two groups was significant (−55.
|
The effect of 12 weeks of antihypertensive therapy with amlodipine on lipid parameters is shown in Table 2.
|
58 MMRM LS Mean (SE) −19.
|
46 1.
|
J Cardiovasc Pharmacol 2000;35:549-55.
|
78 70.
|
80 ± 12.
|
Table 2.
|
indd Sec1:195 Heartnjl.
|
98±4.
|
[21] Subjects Hypertensive patients aged 50–79 years were eligible for inclusion if they had at least one of the following cardiovascular risk factors: a history of stroke, myocardial infarction (MI), stable angina pectoris, coronary artery angioplasty more than 3 months prior to trial commencement, transient ischemic attack, cardiac insufficiency (New York Heart Association [NYHA] class II), peripheral vascular disease, controlled type 2 diabetes mellitus, mild or moderate chronic nephropathy (urine albumin >300 mg/24 h, or blood creatinine >1.
|
Ann Intern Med 1991;114:224.
|
Hart JT.
|
Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis.
|
000500.
|
24) 12 (18.
|
In addition, berberine reversibly inhibits the nicotinamide adenine dinucleotide phosphate (NADPH) oxidasemediated oxidative stress and activates 5´ AMP-activated protein kinase (AMPK), and consequently leads to a reduced expression of lipogenic genes, contributes to an increased oxidation of fatty acids, ameliorates insulin-sensitivity and relieves BP levels [22, 23].
|
To date, there is general consensus that thiazide diuretics and nonselective β-blockers adversely affect lipid levels, but many areas of disagreement exist about the effects of other antihypertensive agents on lipids.
|
0001 LDL-C (mg/dL) Baseline 160.
|
2009;120:2414–2420.
|
1 ± 4.
|
140 Ma et al.
|
55 ± 1 8.
|
7±12.
|
9 58.
|
30 Systolic BP, mm Hg <120 1.
|
A recent member of the valsartan group has been reported to decrease TC levels and apolipoprotein A and B levels significantly in patients with type 2 diabetes or nephropathy (20).
|
The beta blocker effect on the lipid level depends on the.
|
08 to 1.
|
03 0.
|
End of preview. Expand
in Data Studio
- Downloads last month
- 4